Comparison of the Broth Microdilution (BMD) Method of the European Committee on Antimicrobial Susceptibility Testing with the 24-Hour CLSI BMD Method for Testing Susceptibility of Candida Species to Fluconazole, Posaconazole, and Voriconazole by Use of Epidemiological Cutoff Values
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The antifungal broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) was compared with CLSI BMD method M27-A3 for fluconazole, posaconazole, and voriconazole susceptibility testing of 1,056 isolates of Candida . The isolates were obtained in 2009 from more than 60 centers worldwide and included 560 isolates of C. albicans , 175 of C. glabrata , 162 of C. parapsilosis , 124 of C. tropicalis , and 35 of C. krusei . The overall essential agreement (EA) between EUCAST and CLSI results ranged from 96.9% (voriconazole) to 98.6% (fluconazole). The categorical agreement (CA) between methods and species of Candida was assessed using previously determined epidemiological cutoff values (ECVs). The ECVs (expressed as μg/ml) for fluconazole, posaconazole, and voriconazole, respectively, were as follows: 0.12, 0.06, and 0.03 for C. albicans ; 32, 2, and 0.5 for C. glabrata ; 2, 0.25, and 0.12 for C. parapsilosis ; 2, 0.12, and 0.06 for C. tropicalis ; 64, 0.5, and 0.5 for C. krusei . Excellent CA was observed for all comparisons between the EUCAST and CLSI results for fluconazole, posaconazole, and voriconazole, respectively, for each species: 98.9%, 93.6%, and 98.6% for C. albicans ; 96.0%, 98.9%, and 93.7% for C. glabrata ; 90.8%, 98.1%, and 98.1% for C. parapsilosis ; 99.2%, 99.2%, and 96.8% for C. tropicalis ; 97.1%, 97.1%, and 97.1% for C. krusei . We demonstrate high levels of EA and CA between the CLSI and EUCAST BMD methods for testing of triazoles against Candida when the MICs were determined after 24 h and ECVs were used to differentiate wild-type (WT) from non-WT strains. These results provide additional data in favor of the harmonization of these two methods.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Kullberg, B., Sobel, J., Ruhnke, M., Pappas, P., Viscoli, C., Rex, J., Cleary, J., Rubinstein, E., Church, L., Brown, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67490-9 · Cited by 521
Sabatelli, F., Patel, R., Mann, P. A., Mendrick, C. A., Norris, C. C., Hare, R., Loebenberg, D., Black, T. A., & McNicholas, P. M. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00163-06 · Cited by 491 · cited 2×
“Despite the broad utilization of these agents in the prevention and treatment of invasive candidiasis (2, 6, 16, 34), longitudinal surveillance studies have documented the sustained potency of all three triazoles since the introduction of fluconazole in 1990 (8, 9, 18, 21, 25, 28, 31).”
BackgroundPfaller, M. A., Andes, D., Diekema, D. J., Espinel-Ingroff, A., & Sheehan, D. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.09.002 · Cited by 314 · cited 1×
“Although resistance to the triazoles remains relatively uncommon among cases of invasive candidiasis (IC) (19, 23, 25), numerous examples of clinical failure associated with elevated MICs to one or more of these agents have been reported (1, 17, 20, 22, 23, 27).”
BackgroundSelf-citationPfaller, M. A., Diekema, D. J., Rex, J. H., Espinel-Ingroff, A., Johnson, E. M., Andes, D., Chaturvedi, V., Ghannoum, M. A., Odds, F. C., Rinaldi, M. G., et al. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.819-826.2006 · Cited by 258 · cited 2×
“Although resistance to the triazoles remains relatively uncommon among cases of invasive candidiasis (IC) (19, 23, 25), numerous examples of clinical failure associated with elevated MICs to one or more of these agents have been reported (1, 17, 20, 22, 23, 27).”
BackgroundMethodSelf-citation
Cited by
Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment
Pfaller, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.11.001 · Cited by 903
Self-citationPfaller, M. A., & Diekema, D. J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00937-12 · Cited by 484
Self-citationFluconazole-Resistant Candida albicans Vulvovaginitis
Marchaim, D., Lemanek, L., Bheemreddy, S., Kaye, K. S., & Sobel, J. D. (2012) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31827307b2 · Cited by 195
“The breakpoint or measurement of in vitro fluconazole resistance in C albicans had recently been reduced by the Clinical and Laboratory Standards Institution from 64 to 8 micrograms/mL.(14,15) There are limited clinical data, however, based on studies in women with Candida vaginitis suggesting that fluconazole suscept…”
BackgroundEmerging multidrug-resistant Candida species
Colombo, A. L., Júnior, J. N. D. A., & Guinea, J. (2017) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000411 · Cited by 177
Pfaller, M. A., Andes, D., Arendrup, M. C., Diekema, D. J., Espinel-Ingroff, A., Alexander, B. D., Brown, S. D., Chaturvedi, V., Fowler, C. L., Ghannoum, M. A., et al. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.03.002 · Cited by 130
Self-citation
Metadata
- Authors
- Pfaller, M. A., Espinel-Ingroff, A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., & Diekema, D. J.
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2011-03
- Volume
- 49
- Issue
- 3
- Pages
- 845-850
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- OpenAlex
- W2113460689
- Cited by
- 73
- References
- 5
- FWCI
- 6.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of the Broth Microdilution (BMD) Method of the European Committee on Antimicrobial Susceptibility Testing with the 24-Hour CLSI BMD Method for Testing Susceptibility of Candida Species to Fluconazole, Posaconazole, and Voriconazole by Use of Epidemiological Cutoff Values. https://app.cochat.ai/papers/10.1128/jcm.02441-10
- The paper
- Pfaller, M. A., Espinel-Ingroff, A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2011). Comparison of the Broth Microdilution (BMD) Method of the European Committee on Antimicrobial Susceptibility Testing with the 24-Hour CLSI BMD Method for Testing Susceptibility of Candida Species to Fluconazole, Posaconazole, and Voriconazole by Use of Epidemiological Cutoff Values. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.02441-10
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.